您即将离开沛嘉医疗中文官网。
您刚才点击了进入另一网站的链接。如果继续,您可能会进入由第三方运行的网站。 我们不负责对非沛嘉医疗中文官网上的内容进行审核与管控,亦不会对您在非沛嘉医疗中文网上的任何商业交易或事物承担任何责任。您使用其他网站时,必须遵循该网站的使用条款及隐私声明。 其他网站上的部分产品和信息可能并未在您所在地区或国家获得批准。
取消
继续
Brief News on Innovation
Company News Brief News on Innovation
Brief News on Innovation
FIRST PATIENT IMPLANT IN THE GLOBAL CLINICAL STUDYOF THE MonarQ TTVR® SYSTEM
2025.07.16
FIRST PATIENT IMPLANT IN THE GLOBAL CLIN···
This announcement is made by Peijia Medical Limited (the “Company”, together with itssubsidiaries, t···
OCC 2025 One-Year Follow-Up Results from Pivotal Trial of TaurusNXT® Non-glutaraldehyde Crosslinked DrytissueTAVR System Released
2025.05.24
OCC 2025 One-Year Follow-Up Results from···
From May 29 to June 1, 2025, the 19th Oriental Congress of Cardiology (OCC 2025) grandly commenced a···
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of TaurusTrioTM TAVR System Released
2025.05.24
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal clinical trial enrolled 116 symptomatic patients with severe aortic reg···
EuroPCR 2025 30-Day Follow-Up Results from Initial Feasibility Study of Highlife® TSMVR System Released
2025.05.23
EuroPCR 2025 30-Day Follow-Up Results fr···
Highlights: 1. The reported results were derived from a single-center feasibility trial and 7 p···
EuroPCR 2025 One-Year Follow-Up Results from Pivotal Trial of GeminiOne® TEER System Released
2025.05.23
EuroPCR 2025 One-Year Follow-Up Results ···
Highlights: The pivotal trial enrolled 130 patients (including 10 roll-in patients), all of who···
ONE-YEAR FOLLOW-UP RESULTS OF THE REGISTRATION  TRIAL OF TAURUSTRIO™ TAV SYSTEM PRESENTED AT CHINA  VALVE (HANGZHOU) 2025
2025.04.21
ONE-YEAR FOLLOW-UP RESULTS OF THE REGIST···
On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunfeng from Prof. Song ···
REGISTRATION APPLICATION FOR TaurusTrio™ TAV  SYSTEM ACCEPTED BY THE NMPA
2025.04.15
REGISTRATION APPLICATION FOR TaurusTrio™···
On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted the registration app···
HighLife granted US FDA Breakthrough Device Designation for its TMVR solution
2025.04.08
HighLife granted US FDA Breakthrough Dev···
We are thrilled to congratulate our incredible partner HighLife Medical on receiving the U···
SUCCESSFULLY COMPLETION OF THE FIRST TWO IMPLANTSWITH THE TrilogyTM TRANSCATHETER HEART VALVE SYSTEMIN TAIWAN, CHINA
2025.03.05
SUCCESSFULLY COMPLETION OF THE FIRST TWO···
This announcement is made by Peijia Medical Limited (the “ Company”, together with itssubsidiaries, ···
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY  COMPLETED THE FIRST NATIONAL IMPLANTATION  OF THE TAURUSMAXTM TRANSCATHETER AORTIC  VALVE REPLACEMENT SYSTEM
2025.02.10
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY ···
The team led by Academician Ge Junbo from Zhongshan Hospitalaffiliated with Fudan University, includ···
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SUCCESSFULLYCOMPLETED THE FIRST FEE-BASED COMPASSIONATE USETREATMENT IN HONG KONG
2024.11.28
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SU···
In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-developedtranscathet···
PCR London Valves : HighLife® TSMVR SYSTEM (HighLife®) ANNOUNCED THE 1- YEAR CLINICAL FOLLOW-UP RESULTS OF THE FIRST 45 PATIENTS FROM A FEASIBILITY STUDY FOR THE FIRST TIME, LAYING A SOLID EVIDENCE-BASED FOUNDATION FOR FUTURE CE APPROVAL
2024.11.26
PCR London Valves : HighLife® TSMVR SYST···
According to the clinical results, HighLife® achieved atechnical success rate of 89%. At 1 year, the···
Top